Selective Immunoproteasome Inhibition by Novel Once-Weekly Oral Agents Achieves Superior Suppression of Autoimmune Responses with Enhanced Safety Margin Over Subcutaneous Zetomipzomib in Multiple Preclinical Models (ACR Convergence 2026) - Sep 8, 2026 - Abstract #1112; Pres time: Nov 9, 2026; 10:30 AM - 12:30 PM; Location: WB1&2; In Person; "This novel IP inhibitor OPCs demonstrated robust efficacy across rat, mouse, and monkey models, with a favorable safety profile and the added advantage of once-weekly oral dosing, representing a differentiated therapeutic option versus bortezomib and zetomipzomib (Fig.3). Fig.1 OPC-X demonstrated superior disease-suppressive activity compared to zetomipzomib in a murine model of lupus nephritis Fig.2 Once weekly OPC-Z treatment significantly reduced PCs and IgG levels in NHP without inducing thrombocytopenia Fig.3 Differentiation from zetomipzomib and bortezomib"
Preclinical • Autoimmune Hepatitis • Glomerulonephritis • Hematological Disorders • Hepatology • Immunology • Inflammation • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • Renal Disease • Thrombocytopenia
|
|
Ikuo Murakami; Masanori Miyazawa; Kyosuke Mae; Sumie Maeda; Yasuhiro Iwata; Yuya Hoshino; Hiroyuki Yokoi; Yuichi Nakamura; Masamichi Shirakura; Shin Miyamura; Tomohisa Suzuki; Katsuji Hattori
|